Patents by Inventor Laurie B. Schenkel

Laurie B. Schenkel has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Quinazolinones as PARP14 inhibitors
    Patent number: 11958837
    Abstract: The present invention relates to quinazolinones and related compounds which are inhibitors of PARP14 and are useful, for example, in the treatment of cancer and inflammatory diseases.
    Type: Grant
    Filed: April 14, 2021
    Date of Patent: April 16, 2024
    Assignee: Ribon Therapeutics, Inc.
    Inventors: Laurie B. Schenkel, Melissa Marie Vasbinder, Kevin Wayne Kuntz, Kerren Kalai Swinger
  • Quinolines and azaquinolines as inhibitors of CD38
    Patent number: 11952377
    Abstract: The present invention relates to bicyclic heterocycle compounds of Formula (I): and pharmaceutically acceptable salts thereof, which are inhibitors of CD38 and are useful in the treatment of cancer.
    Type: Grant
    Filed: January 28, 2022
    Date of Patent: April 9, 2024
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Jennifer Downing, Kevin Wayne Kuntz, Laurie B. Schenkel, Melissa Marie Vasbinder
  • HETEROBICYCLIC AMIDES AS INHIBITORS OF CD38
    Publication number: 20230312586
    Abstract: The present invention relates to heterobicyclic amides and related compounds which are inhibitors of CD38 and are useful in the treatment of cancer.
    Type: Application
    Filed: December 5, 2022
    Publication date: October 5, 2023
    Inventors: Laurie B. Schenkel, Melissa Marie Vasbinder, Kevin Wayne Kuntz, Nicholas Robert Perl, Jennifer Downing
  • SOLID FORMS OF A PARP14 INHIBITOR
    Publication number: 20230303542
    Abstract: The present invention relates to solid forms of the poly(ADP-ribose) polymerase 14 (PARP14) inhibitor 7-((1-acetylpiperidin-4-yl)methoxy)-5-fluoro-2-(((tetrahydro-2H-pyran-4-yl)thio)methyl)quinazolin-4(3H)-one, including methods of preparation thereof, where the inhibitor is useful in the treatment of cancer and inflammatory diseases.
    Type: Application
    Filed: February 8, 2023
    Publication date: September 28, 2023
    Inventors: Melissa Marie Vasbinder, Laurie B. Schenkel, Kerren Kalai Swinger, Kevin Wayne Kuntz, Nicholas Robert Perl, John Alphons Kremers, Zheng Jane Li, Pengyuan Chen
  • PYRIDAZINONES AS PARP7 INHIBITORS
    Publication number: 20230192664
    Abstract: The present invention relates to pyridazinones and related compounds which are inhibitors of PARP7 and are useful in the treatment of cancer.
    Type: Application
    Filed: October 27, 2022
    Publication date: June 22, 2023
    Inventors: Melissa Marie Vasbinder, Laurie B. Schenkel, Kerren Kalai Swinger, Kevin Wayne Kuntz
  • Pyridazinones as PARP7 inhibitors
    Patent number: 11566020
    Abstract: The present invention relates to pyridazinones and related compounds which are inhibitors of PARP7 and are useful in the treatment of cancer.
    Type: Grant
    Filed: April 12, 2021
    Date of Patent: January 31, 2023
    Assignee: Ribon Therapeutics, Inc.
    Inventors: Melissa Marie Vasbinder, Laurie B. Schenkel, Kerren Kalai Swinger, Kevin Wayne Kuntz
  • QUINAZOLINONES AS PARP14 INHIBITORS
    Publication number: 20230018702
    Abstract: The present invention relates to quinazolinones and related compounds which are inhibitors of PARP14 and are useful, for example, in the treatment of cancer and inflammatory diseases.
    Type: Application
    Filed: April 14, 2021
    Publication date: January 19, 2023
    Inventors: Laurie B. Schenkel, Melissa Marie Vasbinder, Kevin Wayne Kuntz, Kerren Kalai Swinger
  • Heterobicyclic amides as inhibitors of CD38
    Patent number: 11535621
    Abstract: The present invention relates to heterobicyclic amides and related compounds which are inhibitors of CD38 and are useful in the treatment of cancer.
    Type: Grant
    Filed: July 30, 2020
    Date of Patent: December 27, 2022
    Assignee: Ribon Therapeutics, Inc.
    Inventors: Laurie B. Schenkel, Melissa Marie Vasbinder, Kevin Wayne Kuntz, Nicholas Robert Perl, Jennifer Downing
  • TARGETED PROTEIN DEGRADATION OF PARP14 FOR USE IN THERAPY
    Publication number: 20220388985
    Abstract: The present invention relates to quinazolinones and related compounds which degrade PARP14 and are useful, for example, in the treatment of cancer and inflammatory diseases.
    Type: Application
    Filed: June 18, 2020
    Publication date: December 8, 2022
    Inventors: Laurie B. Schenkel, Melissa Marie Vasbinder, Kevin Wayne Kuntz, Kerren Kalai Swinger, Timothy J.N. Wigle
  • METHODS OF TREATING INFLAMMATORY DISEASES
    Publication number: 20220265655
    Abstract: The present invention relates to use of quinazolinones and related compounds which are inhibitors of PARP14 for the treatment and prevention of an inflammatory disease.
    Type: Application
    Filed: January 28, 2022
    Publication date: August 25, 2022
    Inventors: Mario Niepel, Kevin Wayne Kuntz, Laurie B. Schenkel, Kerren Kalai Swinger, Melissa Marie Vasbinder
  • QUINOLINES AND AZAQUINOLINES AS INHIBITORS OF CD38
    Publication number: 20220242862
    Abstract: The present invention relates to compounds which are inhibitors of CD38 and are useful in the treatment of cancer.
    Type: Application
    Filed: January 28, 2022
    Publication date: August 4, 2022
    Inventors: Jennifer Downing, Kevin Wayne Kuntz, Laurie B. Schenkel, Melissa Marie Vasbinder
  • SCREENING METHODS FOR PARP MODULATORS
    Publication number: 20220206008
    Abstract: The present disclosure is related to methods of identifying Poly(ADP-ribose) polymerases (PARP) inhibitors, and the methods of using PARP probes.
    Type: Application
    Filed: March 17, 2022
    Publication date: June 30, 2022
    Inventors: Timothy J.N. Wigle, Danielle J. Blackwell, Kevin Wayne Kuntz, Melissa Marie Vasbinder, Laurie B. Schenkel, Kerren Kalai Swinger
  • SOLID FORMS OF A PARP7 INHIBITOR
    Publication number: 20220162196
    Abstract: The present invention relates to solid forms of the poly(ADP-ribose) polymerase 7 (PARP7) inhibitor 5-[[(2S)-1-(3-oxo-3-[4-[5-(trifluoromethyl)pyrimidin-2-yl]piperazin-1-yl]propoxy)propan-2-yl]amino]-4-(trifluoromethyl)-2,3-dihydropyridazin-3-one, and salts thereof, including methods of preparation thereof, where the inhibitor is useful in the treatment of cancer.
    Type: Application
    Filed: April 28, 2020
    Publication date: May 26, 2022
    Inventors: Melissa Marie Vasbinder, Laurie B. Schenkel, Kerren Kalai Swinger, Kevin Wayne Kuntz, Jun Xu, Meng Jiang, Xin He
  • Screening methods for PARP modulators
    Patent number: 11293927
    Abstract: The present disclosure is related to methods of identifying Poly(ADP-ribose) polymerases (PARP) inhibitors, and the methods of using PARP probes.
    Type: Grant
    Filed: April 29, 2019
    Date of Patent: April 5, 2022
    Assignee: Ribon Therapeutics, Inc.
    Inventors: Timothy J. N. Wigle, Danielle J. Blackwell, Kevin Wayne Kuntz, Melissa Marie Vasbinder, Laurie B. Schenkel, Kerren Kalai Swinger
  • Pyridazinones as PARP7 inhibitors
    Patent number: 11014913
    Abstract: The present invention relates to pyridazinones and related compounds which are inhibitors of PARP7 and are useful in the treatment of cancer.
    Type: Grant
    Filed: August 11, 2020
    Date of Patent: May 25, 2021
    Assignee: Ribon Therapeutics, Inc.
    Inventors: Melissa Marie Vasbinder, Laurie B. Schenkel, Kerren Kalai Swinger, Kevin Wayne Kuntz
  • Quinazolinones as PARP14 inhibitors
    Patent number: 11008308
    Abstract: The present invention relates to quinazolinones and related compounds which are inhibitors of PARP14 and are useful, for example, in the treatment of cancer and inflammatory diseases.
    Type: Grant
    Filed: January 6, 2020
    Date of Patent: May 18, 2021
    Assignee: Ribon Therapeutics Inc.
    Inventors: Laurie B. Schenkel, Melissa Marie Vasbinder, Kevin Wayne Kuntz, Kerren Kalai Swinger
  • HETEROBICYCLIC AMIDES AS INHIBITORS OF CD38
    Publication number: 20210032251
    Abstract: The present invention relates to heterobicyclic amides and related compounds which are inhibitors of CD38 and are useful in the treatment of cancer.
    Type: Application
    Filed: July 30, 2020
    Publication date: February 4, 2021
    Inventors: Laurie B. Schenkel, Melissa Marie Vasbinder, Kevin Wayne Kuntz, Nicholas Robert Perl, Jennifer Downing
  • PYRIDAZINONES AS PARP7 INHIBITORS
    Publication number: 20210024502
    Abstract: The present invention relates to pyridazinones and related compounds which are inhibitors of PARP7 and are useful in the treatment of cancer.
    Type: Application
    Filed: August 11, 2020
    Publication date: January 28, 2021
    Inventors: Melissa Marie Vasbinder, Laurie B. Schenkel, Kerren Kalai Swinger, Kevin Wayne Kuntz
  • Pyridazinones as PARP7 inhibitors
    Patent number: 10870641
    Abstract: The present invention relates to pyridazinones and related compounds which are inhibitors of PARP7 and are useful in the treatment of cancer.
    Type: Grant
    Filed: October 24, 2019
    Date of Patent: December 22, 2020
    Assignee: Ribon Therapeutics, Inc.
    Inventors: Melissa Marie Vasbinder, Laurie B. Schenkel, Kerren Kalai Swinger, Kevin Wayne Kuntz
  • QUINAZOLINONES AS PARP14 INHIBITORS
    Publication number: 20200247788
    Abstract: The present invention relates to quinazolinones and related compounds which are inhibitors of PARP14 and are useful, for example, in the treatment of cancer and inflammatory diseases.
    Type: Application
    Filed: January 6, 2020
    Publication date: August 6, 2020
    Inventors: Laurie B. Schenkel, Melissa Marie Vasbinder, Kevin Wayne Kuntz, Kerren Kalai Swinger